Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(10%)

Phase Distribution

Ph phase_2
8
80%
Ph not_applicable
1
10%
Ph phase_1
1
10%

Phase Distribution

1

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
8(80.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 8 finished

Non-Completion Rate

100.0%

8 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Terminated(8)
Other(1)

Detailed Status

Withdrawn7
Not yet recruiting1
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (10.0%)
Phase 28 (80.0%)
N/A1 (10.0%)

Trials by Status

not_yet_recruiting110%
unknown110%
terminated110%
withdrawn770%

Recent Activity

0 active trials
Showing 5 of 10
not_yet_recruitingphase_2

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

NCT07231575
withdrawnphase_2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

NCT00227773
withdrawnphase_2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

NCT00253526
terminatedphase_2

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

NCT00390364
withdrawnphase_1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

NCT00052403
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07231575Phase 2

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

Not Yet Recruiting
NCT00227773Phase 2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Withdrawn
NCT00253526Phase 2

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Withdrawn
NCT00390364Phase 2

Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy

Terminated
NCT00052403Phase 1

Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors

Withdrawn
NCT00072540Phase 2

S0212 Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix

Withdrawn
NCT01105364Not Applicable

Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer

Unknown
NCT00112879Phase 2

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Withdrawn
NCT00025051Phase 2

Celecoxib in Preventing Skin Cancer

Withdrawn
NCT00244920Phase 2

Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
10